BioMarin Pharmaceutical Inc. (BMRN) vs Madrigal Pharmaceuticals, Inc. (MDGL)

A side-by-side comparison of BioMarin Pharmaceutical Inc. and Madrigal Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
BioMarin Pharmaceutical Inc. logo
BMRN
BioMarin Pharmaceutical Inc.
$10.99B
$56.84HealthcareDelayed quote: Oct 6, 2026, 10:55 AM EDT
Madrigal Pharmaceuticals, Inc. logo
MDGL
Madrigal Pharmaceuticals, Inc.
$11.16B
$483.11HealthcareDelayed quote: Oct 6, 2026, 10:55 AM EDT

Total return — BMRN vs MDGL

growth of $100 · dividends reinvested · last 10y
BMRN -39.5% (-4.9%/yr)MDGL +2930.2% (+40.7%/yr)MDGL compounded faster over this window
Log scale — wide-divergence pair
101001k10kStart $10020182020202220242026$60$3,030
BMRN MDGL

BMRN vs MDGL: by the numbers

  • •MDGL is the larger company ($11.16B vs $10.99B market cap).
  • •BMRN is profitable (2.14% net margin) while MDGL runs a net loss (-25.32%).

Metrics side by side

Valuation

MetricBMRNMDGL
P/E ratio145.74N/A
P/S ratio3.228.69
P/B ratio1.7421.31
EV / EBITDA33.58N/A
FCF yield6.67%N/A

Profitability

MetricBMRNMDGL
Gross margin75.55%91.48%
Operating margin16.56%-25.13%
Net margin2.14%-25.32%
ROE1.15%-62.07%
ROIC1.40%-37.02%

Growth (annualized)

MetricBMRNMDGL
Revenue CAGR (5Y)12.19%N/A
EPS CAGR (5Y)-17.46%N/A
FCF CAGR (5Y)33.84%N/A
Total return CAGR (5Y)-5.59%44.41%

Frequently asked

Is BMRN or MDGL more profitable?
BMRN runs the higher net margin — BMRN at 2.14% versus MDGL at -25.32%.
How have BMRN and MDGL total returns compared?
Over the past 10 years, BMRN delivered -4.98% and MDGL delivered 41.50% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BMRN analysisFull MDGL analysisInteractive comparison tool

Dig into the metrics

BioMarin Pharmaceutical P/E ratioBioMarin Pharmaceutical ROEMadrigal Pharmaceuticals ROEBioMarin Pharmaceutical operating marginMadrigal Pharmaceuticals operating marginBioMarin Pharmaceutical revenue growthMadrigal Pharmaceuticals revenue growthBioMarin Pharmaceutical free cash flowMadrigal Pharmaceuticals free cash flow

BioMarin Pharmaceutical & Madrigal Pharmaceuticals appear in these rankings

Highest FCF Yield StocksHighest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.